Testim and Striant - Two New Testosterone Products
Two new topical testosterone products, a 1% gel (Testim) and a buccal tablet (Striant), have been approved by the FDA for treatment of hypogonadism in men. This review briefly describes hypogonadism and its causes and lists other available formulations of testosterone. For the new products, information on pharmocokinetics, adverse effects, and dosage and administration is provided, as well as a summary of clinical trial results. A dosage and cost table for topical testosterone products is also included. The conclusion summarizes the safety and effectiveness of the new drugs and discusses the potential risks and benefits of using testosterone replacement therapy in older men....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Testim and Striant - Two New Testosterone Products
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1164
Article Code: 1164b
Date: September 1, 2003
Volume: 45
Pages: 70-72
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1164
Article Code: 1164b
Date: September 1, 2003
Volume: 45
Pages: 70-72
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)